About

Synthego specializes in biotechnology, focusing on genetic engineering by providing synthetic RNA and gene editing tools. Their products enable scientists to modify genes, which can lead to advancements in disease treatment and agricultural improvements. Synthego serves a variety of clients, including research institutions, pharmaceutical companies, and biotech startups, who utilize these tools for drug discovery, disease modeling, and genetic research. The company stands out in the growing genetic engineering market by offering a platform that grants users access to advanced gene editing capabilities, alongside their synthetic RNA products. Synthego's goal is to support and enhance genetic research and applications, positioning itself as a vital resource in the field.

Simplify's Take

What believers are saying

• Synthego's GMP facility expansion meets growing demand for CRISPR-based therapies.
• The invalidation of Agilent's patents allows Synthego to innovate freely.
• Partnership with bit.bio enhances Synthego's capabilities in cell therapy development.

What critics are saying

• Emerging CRISPR companies threaten Synthego's market share with innovative solutions.
• Rapid technological advancements may render Synthego's technologies obsolete.
• Potential ethical concerns could lead to stricter regulations affecting operations.

What makes Synthego unique

• Synthego integrates machine learning and automation for scalable genome engineering platforms.
• The company offers a full-stack platform combining hardware, software, and bioinformatics.
• Synthego's focus on synthetic RNA and gene editing tools sets it apart.

Help us improve and share your feedback! Did you find this helpful?

YesNo